NAS10026,630−6.36%S&P7,354−4.36%GOLD$4,075−0.93%BTC$76,040+0.13%VIX26.62−5.54%latest tape · as of 12:04 UTC
The Screen · Consumer Cyclical · Auto Parts
Adient plc
ADNT · the NYSE · USD · Market cap $1.3B · 65,000 employees
Adient plc engages in the design, development, manufacture, and market of seating systems and components for passenger cars, commercial vehicles, and light trucks in United States.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.32, read 2026-11-05
Ethical passes the values gate
Price17.07 USD
Fair value30.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-04Read Accumulation16.92+0.9% to today ✓Markdown gives way to Accumulation
2026-10-31Read Markdown16.69+2.3% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-30Read Accumulation17.35-1.6% to today Markdown gives way to Accumulation
2026-10-28Read Markdown17.12-0.3% to today ✓Accumulation gives way to Markdown first Markdown read since October
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Adient plc holds its Markdown at $17.07. The statistical read favours the sellers, held for 166 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 166 days
Price at the screen
$17.07
Valuation
31.25 trailing · 4.48 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.65
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.77%
Below 33%
Interest-bearing debt is just 26.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
31.62%
Below 49%
Money owed to the company is 31.6% of assets, under the 49% limit.
Pass
Revenue purity
0.17%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Adient clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 27%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ADNT's ethical verdict changes
Today ADNT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 43% discount to our $30.00 fair value, 5.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 43.1% discount to the base estimate.
Where our models see it going: fair-value estimate $30.00, with a range of $30.00 to $34.14, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Car Seat Maker Trades Like a Broken Business
Think of Adient as the firm stitching together every car seat from Detroit to Shanghai. The business supplies complete seating systems to global automakers, yet it posts zero profit margins and just 7% return on equity while revenue edges up only 7%. The forward multiple sits at 6.1 times, which looks tempting until you remember this is a classic cyclical auto supplier.
We pass because low multiples on peak-cycle earnings often signal trouble rather than opportunity. Analysts see a buy with a $29 median target, but the zero margin and thin returns show the company struggles to keep any value after paying suppliers and labour. Ethical checks clear, yet the numbers still fail to justify ownership.
Cyclical swings in vehicle production can wipe out those apparent bargains fast, and an unknown moat leaves little protection when the next downturn hits. The 83% gap to our fair value number does not change the trap. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ADNT trades on the NYSE (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$17.30+3.7%Entry 18
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$16.69+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$16.69+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown · changed$16.69-3.8%Entry 15
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$17.26+0.8%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown · changed$17.12+0.0%Entry 12
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31.
2026-10-18Markdown$18.18+3.8%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (12 analysts) rates it buy, with a mean price target of $31.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
